Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01LRM
|
|||
| Former ID |
DIB001976
|
|||
| Drug Name |
SBC-014
|
|||
| Synonyms |
AVI-014; Glycosylated recombinant G-CSF (neutropenia), AviGenics; Glycosylated recombinant G-CSF (neutropenia), Synageva
Click to Show/Hide
|
|||
| Indication | Neutropenia [ICD-11: 4B00.0; ICD-9: 288] | Phase 2 | [1] | |
| Company |
Synageva BioPharma Corp
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Granulocyte colony-stimulating factor receptor (G-CSF-R) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00497809) Safety and Efficacy Study of GCSF Therapy to Treat Patients at High Risk for Chemotherapy Induced Severe Neutropenia. U.S. National Institutes of Health. | |||
| REF 2 | A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study. BMC Clin Pharmacol. 2009; 9: 2. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.